New hope for advanced breast cancer: umbrella trial tests smart drug combos
NCT ID NCT05933395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing several drug combinations (fulvestrant plus either neratinib, alpelisib, or everolimus) in 135 postmenopausal women with advanced ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitor treatment. The goal is to see which combination offers the best chance of stabilizing or shrinking tumors. Participants are assigned to a treatment arm based on their tumor's genetic profile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fulvestrant, neratinib, alpelisib, everolimus
What this could lead to
If successful, this could identify effective drug combinations for patients whose cancer has stopped responding to standard CDK4/6 inhibitors, potentially slowing disease progression.
What could go wrong
This is a mid-stage trial with only 135 participants, so results may not apply to all patients. Side effects from the drug combinations could be significant, and not all arms may show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••